TCL1, also known as T-cell leukemia/lymphoma protein 1A, protein p14 TCL1 and oncogene TCL-1, is a 14kD beta-barrel protein that was originally identified on the basis of its association with T-cell prolymphocytic leukemia (T-PLL). Activated by the T-cell receptor enhancer through inv(14)(q11;q32.1) or t(14;14)(q11;q32.1), TCL1 is normally expressed in immature cortical thymocytes, activated peripheral T-cells, pro-B cells, and naive mantle zone B cells of peripheral lymphoid tissues, but not in post-germinal center (GC) memory B cells and plasma cells. Akt and TCL1 interact via Akt’s pleckstrin homology domain to form hetero-oligomers at the leaflet of the inner plasma membrane stimulating the protein kinase C-mitogen activated protein kinase-extracellular signal-related kinase (PKC-MAPK-ERK) signal transduction pathway. TCL1 also inhibits activation-induced cell death in T-cells by blocking PKCθ. In addition to T-PLL dysregulation is implicated in such B-cell neoplasias as lymphoblastic lymphoma, chronic lymphocytic leukemia (CLL) and Burkitt lymphoma.

PRODUCT DETAILS

Clone: 1-21

Antibody Type: Monoclonal

Reactivity: Human

Format: PE

Host: Mouse

Isotype: IgG2b, κ

Applications: ICFC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.